Abstract: A turbine housing clamping connection for a turbine, and a turbine having a turbine housing clamping connection are described herein. The turbine housing clamping connection has a bearing housing, a turbine housing and a clamping component comprising a clamping flange clamped between a bearing housing clamping portion of the bearing housing and a turbine housing clamping portion of the turbine housing. The clamping flange has a bearing-housing-side clamping surface comprising a convexly curved clamping surface region. Furthermore, the convexly curved clamping surface region defines a minimum radius of curvature. A ratio of the minimum radius of curvature to an inner radius of the clamping surface is at least 0.1 and/or at most 10, and preferably at least 0.5 and/or at most 2.0, and more preferably at least 1.0 and/or at most 1.4.

Abstract: A turbine housing clamping connection for a turbine, and a turbine having a turbine housing clamping connection are described herein. The turbine housing clamping connection has a bearing housing, a turbine housing and a clamping component comprising a clamping flange clamped between a bearing housing clamping portion of the bearing housing and a turbine housing clamping portion of the turbine housing. The clamping flange has a bearing-housing-side clamping surface comprising a convexly curved clamping surface region. Furthermore, the convexly curved clamping surface region defines a minimum radius of curvature. A ratio of the minimum radius of curvature to an inner radius of the clamping surface is at least 0.1 and/or at most 10, and preferably at least 0.5 and/or at most 2.0, and more preferably at least 1.0 and/or at most 1.4.

Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the Transmembrane protease, serine 6 (TMPRSS6) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a TMPRSS6 gene and to methods of preventing and treating a TMPRSS6-associated disorder, e.g., a disorder associated with iron overload and/or a disorder of ineffective erythropoiesis, e.g., hereditary hemochromatosis, ?-thalassemia (e.g., ?-thalassemia major and ?-thalassemia intermiedia), polycythemia vera, myelodysplastic syndrome, congenital dyserythropoietic anemias, pyruvate kinase deficiency, erythropoietic porphyria, Parkinson's Disease, Alzheimer's Disease or Friedreich's Ataxia.

Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the Transmembrane protease, serine 6 (TMPRSS6) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a TMPRSS6 gene and to methods of preventing and treating a TMPRSS6-associated disorder, e.g., a disorder associated with iron overload and/or a disorder of ineffective erythropoiesis, e.g., hereditary hemochromatosis, ?-thalassemia (e.g., ?-thalassemia major and ?-thalassemia intermedia), polycythemia vera, myelodysplastic syndrome, congenital dyserythropoietic anemias, pyruvate kinase deficiency, erythropoietic porphyria, Parkinson's Disease, Alzheimer's Disease or Friedreich's Ataxia.

Abstract: The invention relates methods of using RNAi agents to inhibit expression of HAO1 and methods of treating subjects having primary hyperoxaluria, e.g., PH1.

Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the Transmembrane protease, serine 6 (TMPRSS6) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a TMPRSS6 gene and to methods of preventing and treating a TMPRSS6-associated disorder, e.g., a disorder associated with iron overload and/or a disorder of ineffective erythropoiesis, e.g., hereditary hemochromatosis, ?-thalassemia (e.g., ?-thalassemia major and ?-thalassemia intermiedia), polycythemia vera, myelodysplastic syndrome, congenital dyserythropoietic anemias, pyruvate kinase deficiency, erythropoietic porphyria, Parkinson's Disease, Alzheimer's Disease or Friedreich's Ataxia.